Answers are grounded in this paper and cite their sources.
// Sohei Kobayashi 1, 2 , Takaki Hiwasa 3 , Takahiro Arasawa 1, 3 , Akiko Kagaya 3, 4 , Sayaka Ishii 1, 3 , Hideaki Shimada 5 , Masaaki Ito 5 , Masae Suzuki 1, 3 , Masayuki Kano 1 , Bahityar Rahmutulla 6 , Kouichi Kitamura 2, 7 , Yuji Sawabe 2 , Hideo Shin 8 , Masaki Takiguchi 3 , Fumio Nomura 9 , Hisahiro Matsubara 1 and Kazuyuki Matsushita 2 1 Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan 2 Department of Laboratory Medicine & Division of Clinical Genetics and Proteomics, Chiba University Hospital, Chiba 260-8670, Japan 3 Department of Biochemistry and Genetics, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan 4 Clinical Research Center, Chiba University Hospital, Chiba 260-8670, Japan 5 Department of Gastroenterological Surgery, School of Medicine, Toho University, Tokyo 143-8541, Japan 6 Department of Molecular Oncology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan 7 Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan 8 Department of Neurosurgery, Higashi Funabashi Hospital, Chiba 274-0065, Japan 9 Divisions of Clinical Mass Spectrometry and Clinical Genetics, Chiba University Hospital, Chiba 260-8670, Japan Correspondence to: Kazuyuki Matsushita, email: kmatsu@faculty.chiba-u.jp Keywords: cancer-testis antigen; SEREX; esophageal squamous cell carcinoma; AlphaLISA; gastrointestinal cancers Received: December 27, 2017 Accepted: March 07, 2018 Published: April 06, 2018 ABSTRACT The present study was planned to identify novel serum antibody markers for digestive organ cancers. We have used screening by phage expression cloning and identified novel fourteen antigens in this experiment. The presence of auto-antibodies against these antigens in serum specimens was confirmed by western blotting. As for auto-antibodies against fourteen antigens, AlphaLISA (amplified luminescence proximity homogeneous assay) assay was performed in the sera of gastrointestinal cancers patients to confirm the results. Serum antibody levels against these fourteen recombinant proteins as antigens between healthy donors (HD) and esophageal squamous cell carcinoma (ESCC) patients, gastric cancer (GC), or colon cancer (CC) were compared. The serum levels of all fourteen auto-antibodies were significantly higher in ESCC and GC than those of HD. Among those auto-antibodies, except ECSA2 and CCNL2, were also detected significantly higher levels in CC than those of HD. Receiver operating curve (ROC) revealed similar results except CCNL2 in CC. AUC values calculated by ROC were higher than 0.7 in auto-antibodies against TPI1, HOOK2, PUF60, PRDX4, HS3ST1, TUBA1B, TACSTD2, AKR1C3, BAMBI, DCAF15 in ESCC, auto-antibodies against TPI1, HOOK2, PUF60, PRDX4, TACSTD2, AKR1C3, BAMBI, DCAF15 in GC, and auto-antibodies against TPI1, HOOK2, PUF60 in CC. AUC of the combination of HOOK2 and anti-p53 antibodies in ESCC was observed to be as high as 0.8228. Higher serum antibody levels against ten antigens could be potential diagnostic tool for ESCC. Higher serum antibody levels against eight antigens could be potential diagnostic tool for GC, and serum antibody levels against three antigens could be potential diagnostic tool for CC.
No takes yet. Share an insight, caveat, or question.
Kobayashi et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: